Regulatory Approval

Results in Nature Medicine reveal an immunotherapy that may stop cancer before it starts in high-risk Lynch Syndrome carriers, heralding a new era of prevention.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

Eagle Pharmaceuticals divests its unique post-op nausea drug to France's LXO Group, signaling a strategic pivot to oncology and critical care.

Willow Labs' new Nutu app combines AI coaching with CDC-backed standards, offering a smarter, evidence-based path to lasting metabolic health.

Medtech firm IMPLANET reports a landmark €12.5M revenue year, fueled by strong international sales, US growth, and a strategic pivot into robotics.

A landmark US-Swiss non-profit collaboration aims to navigate complex regulations and bring life-changing ASO therapies to Europe's rarest patients.

Kye Pharma brings SLENYTO®, a first-of-its-kind prescription sleep aid, to Canada, offering relief to children with ASD and SMS and their families.

Pimicotinib, a once-daily pill for tenosynovial giant cell tumor, gains FDA review, offering new hope for patients beyond invasive surgery.

An Austin startup plans to license its 'inherently safe' nuclear technology using existing regulations, potentially sidestepping decades of red tape.

A new video shows Vitestro's Aletta® robot drawing blood. Can this AI-powered device solve staffing shortages and improve patient care worldwide?

New 2025 data reveals an AI platform is slashing costs, improving chronic disease outcomes, and closing health equity gaps for hundreds of clinicians.

VisionWave Holdings launches a major joint venture with Israeli partner AIPHEX, integrating AI, quantum tech, and a key financial contract.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

After resolving manufacturing hurdles, Camurus' self-administered acromegaly treatment Oclaiz is back on track for US approval, promising new hope for patients.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

Savara's potential new therapy for autoimmune PAP, MOLBREEVI, gets a powerful partner in PANTHERx Rare, promising a new era of comprehensive patient care.